Pfizer surged past the target price from our last report as the company had strong third quarter, with a 130% increase in operational revenue compared to 2020. Its operational revenue grew by 7% compared to the previous year's quarter even after excluding direct sales and alliance revenues from their Covid-19 vaccine. The company is on track to create 3 billion doses this year, with at least 1 billion going to low-income and middle-income countries. Additionally, their weekly market share of Cov ....

21 Jan 2022
Pfizer Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 01/22


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pfizer Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 01/22
- Published:
21 Jan 2022 -
Author:
Ishan Majumdar -
Pages:
14 -
Pfizer surged past the target price from our last report as the company had strong third quarter, with a 130% increase in operational revenue compared to 2020. Its operational revenue grew by 7% compared to the previous year's quarter even after excluding direct sales and alliance revenues from their Covid-19 vaccine. The company is on track to create 3 billion doses this year, with at least 1 billion going to low-income and middle-income countries. Additionally, their weekly market share of Cov ....